Christine Zedelmayer Sells 181,219 Shares of Equillium (NASDAQ:EQ) Stock

Equillium, Inc. (NASDAQ:EQ) COO Christine Zedelmayer sold 181,219 shares of the company’s stock in a transaction that occurred on Monday, March 9th. The stock was sold at an average price of $2.00, for a total value of $362,438.00. Following the completion of the transaction, the chief operating officer owned 62,586 shares of the company’s stock, valued at $125,172. The trade was a 74.33% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Christine Zedelmayer also recently made the following trade(s):

• On Thursday, February 19th, Christine Zedelmayer sold 185,937 shares of Equillium stock. The shares were sold at an average price of $1.76, for a total transaction of $327,249.12.
• On Tuesday, December 23rd, Christine Zedelmayer sold 100,000 shares of Equillium stock. The stock was sold at an average price of $1.50, for a total transaction of $150,000.00.
• On Monday, December 15th, Christine Zedelmayer sold 11,900 shares of Equillium stock. The stock was sold at an average price of $1.31, for a total transaction of $15,589.00.
• On Friday, December 12th, Christine Zedelmayer sold 23,804 shares of Equillium stock. The stock was sold at an average price of $1.34, for a total transaction of $31,897.36.

Equillium Stock Performance

EQ opened at $2.07 on Friday. The stock has a market capitalization of $126.04 million, a price-to-earnings ratio of -3.34 and a beta of 1.81. The company has a fifty day moving average of $1.52 and a 200 day moving average of $1.42. Equillium, Inc. has a fifty-two week low of $0.27 and a fifty-two week high of $2.35.

Wall Street Analysts Forecast Growth

EQ has been the topic of a number of research analyst reports. Stifel Nicolaus initiated coverage on Equillium in a research report on Wednesday, February 25th. They issued a “buy” rating and a $5.00 target price on the stock. Wall Street Zen downgraded Equillium from a “hold” rating to a “sell” rating in a research note on Saturday, February 28th. Zacks Research upgraded Equillium to a “hold” rating in a research report on Thursday, February 26th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Equillium in a report on Monday, December 29th. One investment analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $3.00.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of EQ. Janus Henderson Group PLC purchased a new position in shares of Equillium during the 4th quarter worth about $9,057,000. ADAR1 Capital Management LLC grew its stake in shares of Equillium by 0.9% during the fourth quarter. ADAR1 Capital Management LLC now owns 5,608,078 shares of the company’s stock valued at $8,693,000 after buying an additional 48,090 shares during the last quarter. Woodline Partners LP purchased a new stake in shares of Equillium in the third quarter worth approximately $5,018,000. Aberdeen Group plc lifted its stake in shares of Equillium by 523.6% during the 4th quarter. Aberdeen Group plc now owns 2,366,688 shares of the company’s stock worth $3,668,000 after acquiring an additional 1,987,162 shares during the last quarter. Finally, Balyasny Asset Management L.P. boosted its holdings in Equillium by 3.6% during the 4th quarter. Balyasny Asset Management L.P. now owns 2,076,250 shares of the company’s stock valued at $3,218,000 after acquiring an additional 72,602 shares during the period. 27.05% of the stock is owned by hedge funds and other institutional investors.

Equillium Company Profile

Equillium, Inc (NASDAQ: EQ) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat severe autoimmune diseases and prevent organ transplant rejection. The company’s lead therapeutic candidate, EQ001 (itolizumab), is a humanized monoclonal antibody that modulates T-cell activation by targeting the CD6 receptor. Equillium’s pipeline also includes additional biologic candidates aimed at addressing indications such as acute graft-versus-host disease (GVHD) and lupus nephritis.

Founded in 2015 and headquartered in La Jolla, California, Equillium in-licensed itolizumab from Biocon Limited, leveraging the antibody’s established safety profile in earlier clinical studies.